Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma

The aim of this study is to assess safety, efficacy and pharmacokinetic (PK) parameters with alternative dosing schedules of belantamab mafodotin in combination with bortezomib and dexamethasone compared to the approved dosing regimen in participants with relapsed or refractory multiple myeloma (RRMM) who have received at least 2 prior lines of therapy. The study will further characterize the risk of ocular toxicity and impact on efficacy measures and PK evaluations using alternative and approved dosing regimens.

NCT Number	NCT07614360
Lead Sponsor	GlaxoSmithKline
Conditions	Multiple Myeloma
Enrollment	150 participants
Start Date	2026-08-03
Primary Completion	2029-02-28 (estimated)
Study Completion	2031-02-11 (estimated)
Updated on ClinicalTrials.gov	2026-06-24